Emcure Pharmaceuticals Q2 Results
- BSE: 544210
- NSE: EMCURE
- ISIN: INE168P01015
- Sector: Biotechnology & Drugs
BSE
1,417.50
-34.35 (-2.37%)
-34.35 (-2.37%)Volume5.56 K
Updated: Fri 6 Mar, 2026 | 15:27:22
NSE
1,415.80-37.60 (-2.59%)
-37.60 (-2.59%)Volume1.05 L
Updated: Fri 6 Mar, 2026 | 15:40:57
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Quarter ended Sep 25
Note: Comparison is on QoQ basis
Quarterly - Emcure Pharmaceuticals Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 1,935.34 | 1,799.60 | 7.54% | 1,718.01 | 12.65% |
| Depreciation/ Amortization | 104.64 | 99.46 | 5.22% | 96.90 | 8.00% |
| Operating Income | 334.48 | 300.93 | 11.15% | 283.98 | 17.78% |
| Net Income | 243.46 | 206.95 | 17.64% | 194.57 | 25.13% |
| Other Operating Expenses Total | 556.55 | 501.16 | 11.05% | 476.85 | 16.71% |
| Net Income Before Taxes | 341.42 | 290.76 | 17.42% | 273.41 | 24.87% |
| Total Revenue | 2,269.82 | 2,100.54 | 8.06% | 2,001.98 | 13.38% |
| Selling/ General/ Admin Expenses Total | 384.62 | 393.47 | -2.25% | 355.59 | 8.16% |
| Diluted Normalized EPS | 12.85 | 11.06 | 16.22% | 10.33 | 24.39% |